Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04 2017 - 8:00AM
Business Wire
Presentation on Wednesday, January 11, 2017, at
5:00 p.m. Pacific Time
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing CODIT™ (Characterized Oral
Desensitization ImmunoTherapy) treatments for
life-threatening food allergies, today announced that CEO Stephen
Dilly, M.B.B.S., Ph.D., will present a company overview at the 35th
Annual J.P. Morgan Healthcare Conference in San Francisco on
Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time.
A live audio webcast of the presentation and breakout session
will be accessible from the Investor Relations section of the
Aimmune website at www.aimmune.com. A replay of the webcast will be
available at www.aimmune.com for up to 90 days following the
event.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized
Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of
protection by desensitizing patients with defined, precise amounts
of key allergens. Aimmune’s first investigational product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a
characterized, regulated, oral biological drug product containing
the protein profile found in peanuts. For more information, please
see www.aimmune.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170104005451/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2024 to May 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From May 2023 to May 2024